A number of TNF inhibitors are currently licensed for the treatment of RA and IBD,56,57 and a comparison of their ability to correct intestinal inflammation and permeability, as well as RA symptoms, would be warranted. The gene discussed is TNF; the disease is rheumatoid arthritis.